Evidence map›Paper›PMID 23176705›Full record

ReviewRespiratory research2012

Statins as potential therapeutic drug for asthma?

Cheng Yuan, Lin Zhou, Jiyun Cheng, Jingying Zhang, Yue Teng, Mao Huang, Ian M Adcock, Peter J Barnes, Xin Yao

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Respiratory research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03896217 (A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03896217 phase2completednot on this mapstarted 2019, after this paper: background citation

A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage

TypeinterventionalSponsorUniversity College, LondonRan2019 to 2023Enrolled40ConditionsSecondary Progressive Multiple SclerosisArmsSimvastatin
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Statins for asthma.The Cochrane database of systematic reviews · 2020
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Innovations in asthma therapy: is there a role for inhaled statins?Expert review of respiratory medicine · 2018
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Cheng YuanDepartment of Respiratory Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, China.
Lin Zhou
Jiyun Cheng
Jingying Zhang
Yue Teng
Mao Huang
Ian M Adcock
Peter J Barnes
Xin Yao
Nanjing Medical University · CNJiangsu Province Hospital · CNImperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStatins are lipid-lowering agents that also exhibit pleiotropic effects in decreasing oxidative stress and inflammation. There have been several published studies reporting the use of statins in the treatment of asthma patients, but their results are not consistent. The aim of this study is to determine whether statins are beneficial for asthma administration, and explore the potential covariables that may affect their clinical effectiveness.

methodsA systematic literature search was performed in PubMed, Embase and Cochrane Center Register of Controlled Trials from inception to September 2012. Randomized controlled trials (RCT), retrospective studies and controlled clinical trials which reported the use of statins in the treatment of asthma patients were eligible. Quality evaluation was conducted for RCT using Jadad criteria.

resultsA total of 18 articles were included. In our study, we found no conclusive evidence to demonstrate that statins could enhance the lung function in asthmatics, although, they may reduce airway inflammation. Additionally, the results were not consistent across studies with respect to symptoms, quality of life, maintenance medication, asthma hospitalization/emergency department (ED) visits.

conclusionsStatins may reduce airway inflammation in asthmatics, without having a significant effect on lung function. Further large sample and multicenter clinical trials are needed to confirm this and to see if there are more responsive phenotypes of asthma.

Indexed as

Evidence-Based MedicineQuality of LifeAnimalsAnti-Asthmatic AgentsAsthmaHumansHydroxymethylglutaryl-CoA Reductase InhibitorsPrevalenceRisk FactorsSurvival AnalysisSurvival RateTreatment OutcomeAnti-Asthmatic AgentsHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID23176705
PMCPMC3545889
OpenAlexW2113422649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.